PHARMACOKINETICS/PHARMACODYNAMICS/PHARMACOGENETICS OF DINACICLIB AND DINACICLIB GLUCURONIDE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Zhao, Y. [1 ]
Ling, Y. [1 ]
Poi, M. [1 ]
Schaaf, L. J. [1 ]
Johnson, A. J. [1 ]
Byrd, J. C. [1 ]
Jones, J. A. [1 ]
Phelps, M. A. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-075
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [1] DINACICLIB AND DINACICLIB GLUCURONIDE PHARMACOKINETICS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
    Zhao, Y.
    Ling, Y.
    Kolli, S.
    Poi, M.
    Schaaf, L. J.
    Johnson, A. J.
    Byrd, J. C.
    Jones, J. A.
    Phelps, M. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S95 - S95
  • [2] Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia
    Ghia, Paolo
    Scarfo, Lydia
    Perez, Susan
    Pathiraja, Kumudu
    Derosier, Martha
    Small, Karen
    Sisk, Christine McCrary
    Patton, Nigel
    BLOOD, 2017, 129 (13) : 1876 - 1878
  • [3] A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib Compared to Ofatumumab in Patients with Refractory Chronic Lymphocytic Leukemia
    Ghia, Paolo
    Scarfo, Lydia
    Pathiraja, Kumudu
    Derosier, Martha
    Small, Karen
    Patton, Nigel
    BLOOD, 2015, 126 (23)
  • [4] Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
    Fabre, Claire
    Gobbi, Marco
    Ezzili, Cyrine
    Zoubir, Mustapha
    Sablin, Marie-Paule
    Small, Karen
    Im, Ellie
    Shinwari, Nabeegha
    Zhang, Da
    Zhou, Honghong
    Le Tourneau, Christophe
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1057 - 1064
  • [5] Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
    Claire Fabre
    Marco Gobbi
    Cyrine Ezzili
    Mustapha Zoubir
    Marie-Paule Sablin
    Karen Small
    Ellie Im
    Nabeegha Shinwari
    Da Zhang
    Honghong Zhou
    Christophe Le Tourneau
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1057 - 1064
  • [6] Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia
    Chen, Yixiang
    Germano, Sandra
    Clements, Chris
    Samuel, Jesvin
    Shelmani, Ghalia
    Jayne, Sandrine
    Dyer, Martin J. S.
    Macip, Salvador
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (04) : 641 - 651
  • [7] Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
    Flynn, J.
    Jones, J.
    Johnson, A. J.
    Andritsos, L.
    Maddocks, K.
    Jaglowski, S.
    Hessler, J.
    Grever, M. R.
    Im, E.
    Zhou, H.
    Zhu, Y.
    Zhang, D.
    Small, K.
    Bannerji, R.
    Byrd, J. C.
    LEUKEMIA, 2015, 29 (07) : 1524 - 1529
  • [8] Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
    Flynn, Joseph M. M.
    Andritsos, Leslie A.
    Jones, Jeffrey A.
    Johnson, Amy J.
    Maddocks, Kami
    Wiley, Elizabeth
    Small, Karen
    Im, Eun Kyung
    Grever, Michael R.
    Bannerji, Rajat
    Byrd, John C.
    Zhou, Honghong
    BLOOD, 2013, 122 (21)
  • [9] PHASE I STUDY OF THE CYCLIN-DEPENDENT KINASE (CDK) INHIBITOR DINACICLIB (SCH 727965) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Jones, J.
    Flynn, J.
    Andritsos, L.
    Johnson, A.
    Blum, K.
    Wiley, E.
    Small, K.
    Grever, M.
    Graef, T.
    Bannerji, R.
    Byrd, J.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [10] Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
    Zhang, Da
    Mita, Monica
    Shapiro, Geoffrey I.
    Poon, Jennifer
    Small, Karen
    Tzontcheva, Anjela
    Kantesaria, Bhavna
    Zhu, Yali
    Bannerji, Rajat
    Statkevich, Paul
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 891 - 898
12345